Search Results - "Sung, Pamela J"

KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs by Yan, Fangxue, Li, Jinyang, Milosevic, Jelena, Petroni, Ricardo, Liu, Suying, Shi, Zhennan, Yuan, Salina, Reynaga, Janice M, Qi, Yuwei, Rico, Joshua, Yu, Sixiang, Liu, Yiman, Rokudai, Susumu, Palmisiano, Neil, Meyer, Sara E, Sung, Pamela J, Wan, Liling, Lan, Fei, Garcia, Benjamin A, Stanger, Ben Z, Sykes, David B, Blanco, M Andrés

“…Epigenetic programs are dysregulated in acute myeloid leukemia (AML) and help enforce an oncogenic state of differentiation arrest. To identify key epigenetic…”
Get more information

Location, location, location: A mini-review of CEBPA variants in patients with acute myeloid leukemia by Faisal, Muhammad Salman, Sung, Pamela J

“…variants are frequently recurring in acute myeloid leukemia (AML). The prognostic significance of mutations has recently undergone a major shift in the 5th…”
Get full text

Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors by Sung, Pamela J., Tsai, Frederick D., Vais, Horia, Court, Helen, Yang, Jun, Fehrenbacher, Nicole, Foskett, J. Kevin, Philips, Mark R.

“…K-Ras4B is targeted to the plasma membrane by a farnesyl modification that operates in conjunction with a polybasic domain. We characterized a…”
Get full text

PIKing the right target in AML by Sung, Pamela J.

Get full text

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia by Awada, Hassan, Abdelmalek, Mina, Cronin, Tara, Baron, Jeffrey, Kashour, Zakariya, Azad, Farhan, Faisal, Muhammad Salman, Faber, Mark, Gravina, Matthew, Sung, Pamela J., Green, Steven D., Przespolewski, Amanda, Thompson, James E., Griffiths, Elizabeth A., Wang, Eunice S.

Get full text

Evaluation of hypereosinophilia in a case of FLT3 -mutant acute myeloid leukemia treated with gilteritinib by Martinez-Gutierrez, Leslie N, Burgher, Blake C, Glynias, Manuel J, Alvarado, Daniel, Griffiths, Elizabeth A, Glenn, Sean T, Sung, Pamela J

“…Acute myeloid leukemias (AMLs) frequently harbor activating mutations in ( ). The use of FLT3 inhibitors (FLT3i) is the standard of care for treatment of newly…”
Get full text

Cytosolic Ras Supports Eye Development in Drosophila by Sung, Pamela J., Rodrigues, Aloma B., Kleinberger, Andrew, Quatela, Steven, Bach, Erika A., Philips, Mark R.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Born to RUNX1 by Sung, Pamela J., Babushok, Daria V.

“…In this issue of Blood , Simon et al evaluated 430 samples from patients with acute myeloid leukemia (AML) for germline and somatic mutations in RUNX family…”
Get full text

FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia by Sung, Pamela J., Selvam, Murugan, Riedel, Simone S., Xie, Hongbo M., Bryant, Katie, Manning, Bryan, Wertheim, Gerald B., Kulej, Katarzyna, Pham, Lucie, Bowman, Robert L., Peresie, Jennifer, Nemeth, Michael J., Levine, Ross L., Garcia, Benjamin A., Meyer, Sara E., Sidoli, Simone, Bernt, Kathrin M., Carroll, Martin

“…Internal tandem duplication mutations in fms-like tyrosine kinase 3 ( FLT3-ITD ) are recurrent in acute myeloid leukemia (AML) and increase the risk of…”
Get full text

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia by Sung, Pamela J., Sugita, Mayumi, Koblish, Holly, Perl, Alexander E., Carroll, Martin

“…Activating mutations in Fms-like tyrosine kinase 3 (FLT3) occur in ∼30% of adult cases of acute myeloid leukemia (AML). Selective second- and third-generation…”
Get full text

Minimal Residual Disease in Acute Myeloid Leukemia by Sung, Pamela J., Luger, Selina M.

“…Opinion statement New technology and improved understanding of the pathogenesis of acute leukemias have allowed for sensitive detection of minimal residual…”
Get full text

Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib by Manur, Rashmi, Sung, Pamela J., Loren, Alison W., Ritchie, Ellen K., Frank, Dale, Bagg, Adam, Geyer, Julia T., Bogusz, Agata M.

Get full text

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia by Awada, Hassan, Abdelmalek, Mina, Cronin, Tara, Baron, Jeffrey, Kashour, Zakariya, Azad, Farhan, Faisal, Muhammad Salman, Faber, Mark, Gravina, Matthew, Sung, Pamela J, Green, Steven D, Przespolewski, Amanda, Thompson, James E, Griffiths, Elizabeth A, Wang, Eunice S

Get full text

LNS8801 inhibits Acute Myeloid Leukemia by Inducing the Production of Reactive Oxygen Species and Activating the Endoplasmic Reticulum Stress Pathway by Lee, Inyoung, Doepner, Miriam, Weissenrieder, Jillian, Majer, Ariana D., Mercado, Sophia, Estell, Angela, Natale, Christopher A., Sung, Pamela J., Foskett, J. Kevin, Carroll, Martin P., Ridky, Todd W.

“…Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is…”
Get full text

Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis by Quatela, Steven E, Sung, Pamela J, Ahearn, Ian M, Bivona, Trever G, Philips, Mark R

“…K-Ras is a member of a family of proteins that associate with the plasma membrane by virtue of a lipid modification that inserts into the membrane and a…”
Get more information

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis by Faber, Mark G., Baron, Jeffrey, Yu, Han, Awada, Hassan, Cronin, Tara L., Thompson, James E., Przespolewski, Amanda, Green, Steven D., Sung, Pamela J., Griffiths, Elizabeth A., Wang, Eunice S.

Get full text

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) by Elshoury, Amro, Yu, Han, Ji, Wenyan, Thompson, James E., Griffiths, Elizabeth A., Przespolewski, Amanda, Green, Steven Daniel, Sung, Pamela J., baAqeel, Sheeba, Awada, Hassan, Wang, Eunice S., Kouides, Peter A.

“…▪ Background: Bleeding and thrombosis are prevalent across all myeloproliferative neoplasm (MPN) subtypes and have significant impact on morbidity and…”
Get full text

FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation by Sung, Pamela J., Sidoli, Simone, Riedel, Simone S., Kulej, Katarzyna, Xie, Hongbo, Manning, Bryan, Tsai, Daniel, Wertheim, Gerald, Garcia, Benjamin A., Meyer, Sara E., Bernt, Kathrin M., Carroll, Martin P.

“…Internal tandem duplication mutations in the Fms-like tyrosine kinase 3 (FLT3-ITD) are frequently recurring in AML and confer a poor prognosis. FLT3 inhibitors…”
Get full text

Cytokine Activation of JAK Kinases Rescues FLT3-Mutant AML from FLT3 Inhibition and Requires PIM Kinases by Sung, Pamela J., Koblish, Holly K., Perl, Alexander E., Carroll, Martin

“…Mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase occur in ~30% of acute myeloid leukemias (AMLs) and are associated with a poor…”
Get full text

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia by Awada, Hassan, Abdelmalek, Mina, Cronin, Tara L., Baron, Jeffrey, Kashour, Zakariya, Azad, Farhan, Faisal, Muhammad Salman, Faber, Mark G., Roy, Arya, Gupta, Ashish, Gravina, Matthew, Ba Aqeel, Sheeba, Taneja, Alankrita, Sung, Pamela J., Green, Steven D., Przespolewski, Amanda, Thompson, James E., Griffiths, Elizabeth A., Wang, Eunice S.

Get full text